Journal of Cutaneous Medicine and Surgery: Introduction

Journal of Cutaneous Medicine and Surgery

Volumn 8, Issue SUPPL. 2, 2004, Pages 1-2

  Sauder, Daniel N ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; METHOTREXATE;

CELL INFILTRATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG POTENCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KERATINOCYTE; MEMORY CELL; PHENOTYPE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; WELLBEING;

EID: 13644269603     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-004-9501-4     Document Type: Review

References (9)

1. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49:S44-S50.
2. Barker JNWN. Psoriasis as a T cell-mediated autoimmune disease. Hosp Med 1998; 59:530-533.
3. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20:40-46.
4. Yamauchi PS, Rizk D, Kormeili T, et al. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 2003; 49:S66-S77.
5. Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol 2003; 49:S78-S86.
6. Choi J, Koo JYM. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49:S57-S61.
7. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41:51-59.
8. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis. The new therapeutic frontier. Arch Dermatol 2002; 138:657-663.
9. Gottlieb AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002; 105:105-116.